TY - JOUR
T1 - Bladder urothelial carcinoma in a child
T2 - Case report and review of literature
AU - Oda, Marian Hanae
AU - Dos Santos, Danilo Vicente
AU - Farias, Adria Karina
AU - de Oliveira, Leilane
AU - Falcão, Bruno Pinheiro
AU - Ahn, Nicholas J.
AU - Amarante, Antônio Carlos
AU - Losso, Graziele Moraes
AU - Dos Santos Dias, Andre Ivan Bradley
AU - Agulham, Miguel Angelo
AU - Fachin, Camila Girardi
N1 - Publisher Copyright:
© 2019 Oda, dos Santos, Farias, de Oliveira, Falcão, Ahn, Amarante, Losso, Dias, Agulham and Fachin.
PY - 2019
Y1 - 2019
N2 - Bladder urothelial carcinoma (UC) it is the fifth most prevalent carcinoma in humans, nevertheless in children and young adults it’s very rare. It usually occurs in older adults. Literature on UC in pediatric population is limited and important information (risk factors, follow-up protocols, etc.) are poorly defined. We present an 11-year-old boy with a painful macroscopic hematuria. Ultrasound revealed a heterogeneous intravesical mass without extravesical extension, which was confirmed by computed tomography (CT) and magnetic resonance imaging (MRI). The first biopsy was compatible with urothelial papilloma. After 1 year, he returned with a bigger mass. Transurethral resection of the bladder (TURB) was performed and immunohistochemistry showed low-grade papillary UC with a high-grade component, with tumor free margin. Tumor had mutations in the BRAF and KRAS genes. Two and a half years after the resection the patient has no recurrence. Less than 1% of bladder UC occur in the first two decades of life. Gross hematuria is a common symptom. Ultrasound is generally the first diagnostic tool. MRI is also helpful, but cystoscopy allows definitive diagnosis. Transurethral resection of the bladder (TURB) is the standard treatment, with good results and low recurrence rate, and it was the treatment of choice for our patient, that remains free of disease. The BRAF and KRAS gene mutations were never described before in pediatric UC. There are only few cases in literature of pediatric UC that present a tumor genetic profile; therefore, our case report adds more information to this very rare disease in children.
AB - Bladder urothelial carcinoma (UC) it is the fifth most prevalent carcinoma in humans, nevertheless in children and young adults it’s very rare. It usually occurs in older adults. Literature on UC in pediatric population is limited and important information (risk factors, follow-up protocols, etc.) are poorly defined. We present an 11-year-old boy with a painful macroscopic hematuria. Ultrasound revealed a heterogeneous intravesical mass without extravesical extension, which was confirmed by computed tomography (CT) and magnetic resonance imaging (MRI). The first biopsy was compatible with urothelial papilloma. After 1 year, he returned with a bigger mass. Transurethral resection of the bladder (TURB) was performed and immunohistochemistry showed low-grade papillary UC with a high-grade component, with tumor free margin. Tumor had mutations in the BRAF and KRAS genes. Two and a half years after the resection the patient has no recurrence. Less than 1% of bladder UC occur in the first two decades of life. Gross hematuria is a common symptom. Ultrasound is generally the first diagnostic tool. MRI is also helpful, but cystoscopy allows definitive diagnosis. Transurethral resection of the bladder (TURB) is the standard treatment, with good results and low recurrence rate, and it was the treatment of choice for our patient, that remains free of disease. The BRAF and KRAS gene mutations were never described before in pediatric UC. There are only few cases in literature of pediatric UC that present a tumor genetic profile; therefore, our case report adds more information to this very rare disease in children.
KW - BRAF
KW - Children
KW - KRAS
KW - Macroscopic hematuria
KW - Urothelial carcinoma
UR - https://www.scopus.com/pages/publications/85072925443
U2 - 10.3389/fped.2019.00385
DO - 10.3389/fped.2019.00385
M3 - Article
AN - SCOPUS:85072925443
SN - 2296-2360
VL - 7
JO - Frontiers in Pediatrics
JF - Frontiers in Pediatrics
IS - SEP
M1 - 385
ER -